Cargando…
WP1066 Sensitizes Oral Squamous Cell Carcinoma Cells to Cisplatin by Targeting STAT3/miR-21 axis
Accumulating evidence reveals that activation of STAT3 and miR-21 contributes to chemoresistance in multiple tumors. We examined the expression of STAT3 and miR-21 in 43 oral squamous cell carcinoma (OSCC) tumors and classified them into cisplatin sensitive or resistant group. Tca8113 and Tca8113/DD...
Autores principales: | Zhou, Xuan, Ren, Yu, Liu, Aiqin, Jin, Rui, Jiang, Qingping, Huang, Yuanyuan, Kong, Lingping, Wang, Xudong, Zhang, Lun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268632/ https://www.ncbi.nlm.nih.gov/pubmed/25514838 http://dx.doi.org/10.1038/srep07461 |
Ejemplares similares
-
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010) -
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3
por: Honda, Shino, et al.
Publicado: (2017) -
WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line
por: Allaf, Abdulrahman, et al.
Publicado: (2022) -
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
por: de Groot, John, et al.
Publicado: (2022) -
Induction of M-MDSCs with IL6/GM-CSF from adherence monocytes and inhibition by WP1066
por: Hu, Hao, et al.
Publicado: (2022)